Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1CNS 1

Conditions

Breast Neoplasms 2Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Stomach Neoplasms 1Solid Tumor Spine Metastases 1Sarcoma 1Rectal Neoplasms 1Oligodendroglioma 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms 1Lymphoma, Follicular 1Locally Advanced Colon Cancer 1Head and Neck Neoplasms 1Glioma 1Glioblastoma 1Colorectal Neoplasms 1Colonic Neoplasms 1Central Nervous System Neoplasms 1Astrocytoma 1Anxiety Disorders 1Amenorrhea 1

Interventions

Temozolomide 159Bevacizumab 69Radiotherapy 68Magnetic Resonance Spectroscopy 68Irinotecan 31Surgical Procedures, Operative 27Radiation 24Carboplatin 23Specimen Handling 20Carmustine 20Blood Specimen Collection 20Nivolumab 19Aminolevulinic Acid 18Biopsy 17Lomustine 16pembrolizumab 13Radiotherapy, Intensity-Modulated 13Cyclophosphamide 13trametinib 12fluorodopa F 18 12X-Rays 12Radiosurgery 12Erlotinib Hydrochloride 12Topotecan 11Everolimus 11Magnetic Resonance Imaging 10IL13-PE38 10dabrafenib 9Etoposide 9Drug Therapy 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioma × Postoperative Period × Clear all
NCT02549833 2024-11-22

Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma

University of California, San Francisco

Phase 1 Completed
28 enrolled
CNSLymphoid

Astrocytoma, Glioma, Lymphoma, Follicular, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡